A Phase 1 Study of Acapatamab, a Half-Life Extended, PSMA-Targeting Bispecific T-Cell Engager for Metastatic Castration-Resistant Prostate Cancer

Patients with metastatic castration-resistant prostate cancer refractory to androgen receptor pathway inhibitor therapy and taxane-based chemotherapy received target acapatamab doses ranging from 0.003 mg–0.9 mg in dose exploration and 0.3 mg in dose expansion intravenously Q2W.